Cargando…
Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study
INTRODUCTION: Several single institution phase I and phase II trials of stereotactic ablative body radiotherapy (SABR) for liver tumors have reported promising results and high local control rates of over 90%. However, there are wide variations in dose and fractionation due to different prescription...
Autores principales: | Eriguchi, Takahisa, Takeda, Atsuya, Oku, Yohei, Ishikura, Satoshi, Kimura, Tomoki, Ozawa, Shuichi, Nakashima, Takeo, Matsuo, Yukinori, Nakamura, Mitsuhiro, Matsumoto, Yasuo, Yamazaki, Sadanori, Sanuki, Naoko, Ito, Yoshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653723/ https://www.ncbi.nlm.nih.gov/pubmed/23641879 http://dx.doi.org/10.1186/1748-717X-8-113 |
Ejemplares similares
-
Role of stereotactic body radiotherapy in multidisciplinary management of liver metastases in patients with colorectal cancer
por: Sanuki, Naoko, et al.
Publicado: (2022) -
Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume
por: Takeda, Atsuya, et al.
Publicado: (2014) -
Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume
por: Tsurugai, Yuichiro, et al.
Publicado: (2019) -
Stereotactic body radiotherapy for T3 and T4N0M0 non–small cell lung cancer
por: Eriguchi, Takahisa, et al.
Publicado: (2016) -
Applying Artificial Neural Networks to Develop a Decision Support Tool for Tis–4N0M0 Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy
por: Nemoto, Takafumi, et al.
Publicado: (2022)